---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-118544"
form_type: "8-K"
ticker: "XLO"
cik: "0001840233"
company_name: "Xilio Therapeutics, Inc."
filed_at: "2026-03-23T23:59:59+00:00"
generated_at: "2026-05-15T09:24:04.170779+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Xilio announces Q4 net income $10.4M, cash $137.5M, runway through 2027

## Summary
- Net income of $10.4M in Q4 2025 vs net loss of $13.1M in Q4 2024; full year net loss narrowed to $35.0M from $58.2M.
- Cash and cash equivalents $137.5M at Dec 31, 2025, up from $55.3M end of 2024; cash runway extended through end of 2027.
- XTX501 (bispecific PD-1/masked IL-2) on track for IND submission mid-2026 and Phase 1 start H2 2026; initial data expected H2 2027.
- Advancing masked T cell engagers: CLDN18.2 program preclinical data at AACR April 2026; PSMA/STEAP1 candidate nomination Q2 2026.
- Recent capital raises: $35.8M from Series B warrant exercises (Jan 2026) and $40.0M follow-on offering (Feb 2026).

## SEC filing metadata
- accession: 0001193125-26-118544
- form_type: 8-K
- ticker: XLO
- cik: 0001840233
- company_name: Xilio Therapeutics, Inc.
- filed_at: 2026-03-23T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840233/000119312526118544/0001193125-26-118544-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840233/000119312526118544/xlo-20260323.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-118544
- JSON: https://secwatch.observer/filing/0001193125-26-118544.json
- Plain text: https://secwatch.observer/filing/0001193125-26-118544.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.